Real-world study of anifrolumab for active lupus
Part of Immune system & allergy, Skin clinical trials.
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic lupus erythematosus (SLE) by a doctor.
- You have active lupus symptoms and your doctor thinks anifrolumab might help.
- You have already started or are about to start anifrolumab treatment.
- You are 18 years or older.
- You agree to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called anifrolumab, which is given as an injection or infusion, to see how it works in people with active lupus. It may help reduce lupus symptoms by targeting the immune system.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
This study tests whether a medicine called anifrolumab can help reduce severe tiredness (fatigue) in people with lupus. It is for adults whose lupus is mostly under control but who still feel very tired.
This study tests whether anifrolumab, a drug that targets the immune system, can improve markers of blood vessel health in people with lupus. It may help reduce the risk of heart problems associated with lupus.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.